Transgene Past Earnings Performance
Past criteria checks 0/6
Transgene's earnings have been declining at an average annual rate of -32.4%, while the Biotechs industry saw earnings growing at 17.8% annually. Revenues have been growing at an average rate of 9.4% per year.
Key information
-32.4%
Earnings growth rate
-53.8%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 9.4% |
Return on equity | -88.3% |
Net Margin | -375.3% |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Transgene makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 9 | -33 | 7 | 0 |
31 Mar 23 | 10 | -33 | 8 | 0 |
31 Dec 22 | 10 | -33 | 8 | 0 |
30 Sep 22 | 14 | -28 | 8 | 0 |
30 Jun 22 | 18 | -23 | 8 | 0 |
31 Mar 22 | 18 | -21 | 8 | 0 |
31 Dec 21 | 17 | -20 | 7 | 0 |
30 Sep 21 | 13 | -23 | 7 | 0 |
30 Jun 21 | 9 | -27 | 6 | 0 |
31 Mar 21 | 9 | -22 | 6 | 0 |
31 Dec 20 | 10 | -17 | 7 | 0 |
30 Sep 20 | 12 | -11 | 7 | 0 |
30 Jun 20 | 14 | -6 | 7 | 0 |
31 Mar 20 | 14 | -12 | 7 | 0 |
31 Dec 19 | 13 | -19 | 7 | 0 |
30 Sep 19 | 11 | -6 | 7 | 0 |
30 Jun 19 | 8 | 8 | 8 | 0 |
31 Mar 19 | 8 | 8 | 7 | 0 |
31 Dec 18 | 7 | 8 | 7 | 0 |
30 Sep 18 | 7 | -10 | 6 | 4 |
30 Jun 18 | 7 | -29 | 6 | 9 |
31 Mar 18 | 7 | -31 | 6 | 15 |
31 Dec 17 | 7 | -32 | 6 | 22 |
30 Sep 17 | 8 | -32 | 6 | 22 |
30 Jun 17 | 9 | -31 | 6 | 22 |
31 Mar 17 | 9 | -28 | 6 | 20 |
31 Dec 16 | 10 | -24 | 6 | 18 |
30 Sep 16 | 10 | -26 | 6 | 19 |
30 Jun 16 | 9 | -28 | 6 | 20 |
31 Mar 16 | 9 | -33 | 6 | 22 |
31 Dec 15 | 10 | -38 | 6 | 24 |
30 Sep 15 | 10 | -40 | 6 | 25 |
30 Jun 15 | 10 | -42 | 7 | 26 |
31 Mar 15 | 11 | -41 | 7 | 26 |
31 Dec 14 | 11 | -41 | 8 | 27 |
30 Sep 14 | 13 | -41 | 7 | 28 |
30 Jun 14 | 15 | -41 | 7 | 30 |
31 Mar 14 | 15 | -42 | 7 | 32 |
31 Dec 13 | 16 | -43 | 7 | 34 |
30 Sep 13 | 15 | -44 | 7 | 34 |
30 Jun 13 | 14 | -45 | 7 | 34 |
31 Mar 13 | 13 | -44 | 7 | 34 |
Quality Earnings: TRGN.F is currently unprofitable.
Growing Profit Margin: TRGN.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: TRGN.F is unprofitable, and losses have increased over the past 5 years at a rate of 32.4% per year.
Accelerating Growth: Unable to compare TRGN.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TRGN.F is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-42.7%).
Return on Equity
High ROE: TRGN.F has a negative Return on Equity (-88.34%), as it is currently unprofitable.